Market Access News | pharmaphorum

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

News

ABPI slams UK government consultation on drug levy

For all the UK government’s rhetoric on supporting the life sciences industry, it seems destined to alienate the very sector it is trying to court.

News

New HTA body pledges to ‘cut the hype’ in digital health

US non-profit the Peterson Centre on Healthcare has launched a new institute, backed with $50 million in funding, that will take a close look at the clinical benefits and

News

Beyfortus cleared by FDA for RSV prevention in infants

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV

News

Changing Faces: Non-profit, professional organisation, and g...

We normally only segment our hires roundup into three categories, but for the May-June double issue we had enough non-profit, professional organisation, and government hires to spin them of

AbbVie nears EU nod for DLBCL drug epcoritamab

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

ABPI slams UK government consultation on drug levy

New HTA body pledges to ‘cut the hype’ in digital health

Beyfortus cleared by FDA for RSV prevention in infants

Changing Faces: Non-profit, professional organisation, and g...

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks